Moksha8 Pharmaceuticals has expanded its partnership with Roche to commercialise an additional portfolio of products in Mexico and Brazil. The company will commercialise products in three therapeutic areas – CNS disease, anti-infectives, and inflammation. The product portfolio covers brands like Rivotril, Rocephin and Bactrim.
Ernest Egli, President of Roche, Latin America, said: “moksha8 has produced strong results for Roche in Brazil and we are delighted to expand our relationship to include Mexico as a key country in Latin America.”
Moksha8 is positioned as the partner of choice for both pharmaceutical and biotechnology companies seeking to capture value from their products in high growth emerging markets.
The company has a strong presence in CNS, anti-infectives and inflammation markets in Latin America.